(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -17.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
C4 Therapeutics's revenue in 2025 is $35,584,000.On average, 2 Wall Street analysts forecast CCCC's revenue for 2025 to be $1,612,814,108, with the lowest CCCC revenue forecast at $1,117,235,285, and the highest CCCC revenue forecast at $2,108,392,932. On average, 2 Wall Street analysts forecast CCCC's revenue for 2026 to be $1,621,687,816, with the lowest CCCC revenue forecast at $1,134,982,700, and the highest CCCC revenue forecast at $2,108,392,932.
In 2027, CCCC is forecast to generate $1,400,767,991 in revenue, with the lowest revenue forecast at $693,143,050 and the highest revenue forecast at $2,108,392,932.